key: cord-0817715-yk0tut30 authors: Sachithanandham, Jaiprasath; Thio, Chloe L; Balagopal, Ashwin title: The natural history of SARS-CoV-2 infection: a composite but incomplete picture date: 2020-09-29 journal: Clin Infect Dis DOI: 10.1093/cid/ciaa1413 sha: 6cd32a6b23526e26becfe0d0eea1b1549b99afc7 doc_id: 817715 cord_uid: yk0tut30 nan A c c e p t e d M a n u s c r i p t The Severe Acute Respiratory Syndrome coronavirus 2 (SARS CoV-2) pandemic began as an outbreak in Wuhan, China [1] and has quickly spread around the world, infecting over 25 million people globally and resulting in >800,000 deaths as of September 1, 2020 [2] . In addition, the SARS-CoV-2 pandemic has had significant impact of nearly all walks of life, stifling economies, travel, and schooling [3] . Ameliorating the pandemic will require a clear understanding of the natural history and transmission of SARS-CoV-2. The SARS-CoV-2 virus causes the collection of symptoms and signs that constitute COVID-19, which typically manifests as an acute respiratory disease with inflammatory and vascular complications. Most evidence points to transmission of SARS-CoV-2 via respiratory droplets and close contact, although airborne transmission may be possible in certain scenarios where aerosols are produced [4] . Despite the rapid advances that have been made to understand the natural history of SARS-CoV-2 infection, there are still several key questions that remain unanswered. Among the most important is the question of how long people remain infectious after acquisition, which has major implications for control of the pandemic. Epidemiologic studies indicate that there have been no transmissions from infected people after 14 days of symptom onset [5] , although SARS-CoV-2 RNA can be detectable for weeks or even months. While the viral culture assay is the current gold standard for infectiousness, it is insensitive and difficult to perform; thus, there is an urgent need for an assay that can distinguish non-infectious from infectious viral shedding. One of the first groups to report viral RNA and infectious titers longitudinally in a cohort of nine people demonstrated that viral cultures were negative after 8 days of symptoms and were only positive when viral RNA levels in nasopharyngeal (NP) swabs were > ~1 million copies [6] . In this study, as in others, viral RNA was measured using quantitative real time PCR (qPCR), a platform that estimates the amount of original template present from the number of PCR doublings of the template required to cross a preset cycling threshold (Ct): the fewer the number of doublings, the more original template, and vice versa. In a larger study of samples from 90 persons who had assays for viral RNA and A c c e p t e d M a n u s c r i p t culture performed, 26 samples were positive, none >8 days after symptom onset, and none were positive if cycle thresholds (Ct) were >= 24 [7] . Similar findings have been reported by two other groups, although notably Gniazdowski et al. report occasional positive cultures up to a Ct of 30 [8] [9] . A corollary to the question of viral culture and transmissibility is whether there is a corresponding host response that appears when transmission is diminished. Several papers have reported the appearance of anti-SARS-CoV-2 antibodies. Importantly, Wolfel et al. reported that antibody seroconversion was associated with a decline in infectious titers and viral RNA. However, there appear to be differing times to seroconversion reported by the groups. In addition, the assays used differ between the studies, and there is now widespread acknowledgement that not all antibody tests are equal. Finally, there has been a plethora of reports of the inflammatory phenotypes that appear to be associated with worse COVID-19 phenotypes. Most recently, Jacobson performed an intensive AI analysis of the host transcriptome from 9 persons with COVID-19 and 40 controls and uncovered a common and potential pathophysiologic link to bradykinin [10] . However, while several cytokines have been linked to disease severity, it has been challenging to identify which cytokines are in the causal pathway of COVID-19 disease and which are triggered by severe infection, but otherwise do not contribute to disease [11] [12] [13] [14] [15] . In 30 patients with available serum specimens longitudinally, the majority of samples had detectable anti-SARS-CoV-2 IgM levels in weeks 2 and 3 after symptom onset, with similar results for IgG. The vast majority of people seroconverted by day 14, and there appeared to be a significant inverse association between the severity of illness and the time to seroconversion. Disease severity and peak titer also appeared to be correlated, which corroborates data from an earlier report [17] . Serum cytokine measurements performed longitudinally in 81 persons showed a largely pro-inflammatory milieu that was associated with disease severity and the need for oxygen, which appears to confirm many contemporaneous reports showing the same. However, details about the 23 healthy controls, such as sex or age, and the variability in the control's cytokine levels are not given; thus, it is not possible to make strong conclusions about the role of cytokines in COVID-19 disease in this cohort. A c c e p t e d M a n u s c r i p t The study by Young et al. is among the largest to date to characterize longitudinal cultures, seroconversion, and cytokine profiles in persons with COVID-19. Notwithstanding its size and ambitious scope, there are still several unanswered questions. Firstly, it is important to develop methods besides culture to determine infectiousness to truly understand the duration of transmissibility. Second, it is somewhat unclear what the selection criteria were that determined which individuals underwent culture, which underwent serostatus measurements, and which underwent cytokine profiling. This is important with regards to whether the appearance of anti-SARS-CoV-2 antibodies was associated with a loss of culture positivity, as was demonstrated by Wolfel et al [6] It would also be of interest to assess whether certain cytokine profiles were associated with viral kinetics or the timing of seroconversion. The relationship between the peak antibody titer and disease severity, in the absence of an association with viral titer or RNA, is both intriguing and confirms previous findings [17] . Taken together with the amalgamation of inflammatory cytokines present during infection, these data suggest that the significant differences in COVID-19 presentation and severity may be more the result of differences in host responses to SARS-CoV-2 than differences in viral replication. However, in the absence of a model system or a controlled perturbation, it is difficult to discern which host responses precipitate COVID-19 severity, and which are bystanders. The past nine months have provided a wealth of data about the SARS-CoV-2 pandemic that has helped clinicians and scientists respond to this global threat. To move to the next phase of understanding will require major efforts to link the numerous disparate phenomenological threads that have been pulled from COVID-19. The present study is a step in that direction. To learn more, multi-modal longitudinal studies that include asymptomatic infected patients with samples collected systematically on everyone are needed to interrogate the distinct arms of virology and host responses, both to elucidate the pathophysiology of COVID-19 and to yield potential new therapies. A c c e p t e d M a n u s c r i p t CT reports grants from the NIH during the conduct of the study and outside the current study. All other authors have no conflicts. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2 Coronavirus Disease-19) WHO Coronavirus Disease (COVID-19) Dashboard Available at The socio-economic implications of the coronavirus pandemic (COVID-19): A review Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 Korea Centers for Disease Control and Prevention. Findings from Investigation and Analysis of re-positive cases Virological assessment of hospitalized patients with COVID-2019 Predicting infectious SARS-CoV-2 from diagnostic samples Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular 2 Assay Cycle Thresholds, and Analytical Sensitivity A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm Cytokine Levels in Critically Ill Patients with COVID-19 and Other Conditions Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19 Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 ARDS The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge An inflammatory cytokine signature predicts COVID-19 severity and survival Viral dynamics and immune correlates of COVID-19 disease severity Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 A c c e p t e d M a n u s c r i p t